Limits...
Non-invasive technology that improves cardiac function after experimental myocardial infarction: Whole Body Periodic Acceleration (pGz).

Uryash A, Bassuk J, Kurlansky P, Altamirano F, Lopez JR, Adams JA - PLoS ONE (2015)

Bottom Line: Ejection fraction and fractional shortening and invasive pressure volume relation indices of afterload and contractility were significantly better in MI-pGz.The latter where associated with decreased infarct transmurality and decreased fibrosis along with increased eNOS, p-eNOS.Additionally, MI-pGz had significantly lower levels of iNOS, inflammatory cytokines (IL-6, TNF-α), and higher level of anti-inflammatory cytokine (IL-10). pGz improved survival and contractile performance, associated with improved myocardial remodeling. pGz may serve as a simple, safe, non-invasive therapeutic modality to improve myocardial function after MI.

View Article: PubMed Central - PubMed

Affiliation: Division of Neonatology, Mount Sinai Medical Center, Miami Beach, FL, United States of America.

ABSTRACT
Myocardial infarction (MI) may produce significant inflammatory changes and adverse ventricular remodeling leading to heart failure and premature death. Pharmacologic, stem cell transplantation, and exercise have not halted the inexorable rise in the prevalence and great economic costs of heart failure despite extensive investigations of such treatments. New therapeutic modalities are needed. Whole Body Periodic Acceleration (pGz) is a non-invasive technology that increases pulsatile shear stress to the endothelium thereby producing several beneficial cardiovascular effects as demonstrated in animal models, normal humans and patients with heart disease. pGz upregulates endothelial derived nitric oxide synthase (eNOS) and its phosphorylation (p-eNOS) to improve myocardial function in models of myocardial stunning and preconditioning. Here we test whether pGz applied chronically after focal myocardial infarction in rats improves functional outcomes from MI. Focal MI was produced by left coronary artery ligation. One day after ligation animals were randomized to receive daily treatments of pGz for four weeks (MI-pGz) or serve as controls (MI-CONT), with an additional group as non-infarction controls (Sham). Echocardiograms and invasive pressure volume loop analysis were carried out. Infarct transmurality, myocardial fibrosis, and markers of inflammatory and anti-inflammatory cytokines were determined along with protein analysis of eNOS, p-eNOS and inducible nitric oxide synthase (iNOS).At four weeks, survival was 80% in MI-pGz vs 50% in MI-CONT (p< 0.01). Ejection fraction and fractional shortening and invasive pressure volume relation indices of afterload and contractility were significantly better in MI-pGz. The latter where associated with decreased infarct transmurality and decreased fibrosis along with increased eNOS, p-eNOS. Additionally, MI-pGz had significantly lower levels of iNOS, inflammatory cytokines (IL-6, TNF-α), and higher level of anti-inflammatory cytokine (IL-10). pGz improved survival and contractile performance, associated with improved myocardial remodeling. pGz may serve as a simple, safe, non-invasive therapeutic modality to improve myocardial function after MI.

No MeSH data available.


Related in: MedlinePlus

pGz Reduced Infarct Size, Transmurality and Fibrosis.A. The ratio of left ventricular wall to myocardial infarct length in MI-CONT and MI-pGz, with representative microscopic findings. †p< 0.01 MI-CONT vs. MI-pGz. B. Left Ventricular Collagen as a % of the left ventricle in MI-CONT and MI-pGz, with representative microscopic findings. Blue staining denotes fibrosis †p< 0.01 MI-CONT vs. MI-pGz.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4373845&req=5

pone.0121069.g003: pGz Reduced Infarct Size, Transmurality and Fibrosis.A. The ratio of left ventricular wall to myocardial infarct length in MI-CONT and MI-pGz, with representative microscopic findings. †p< 0.01 MI-CONT vs. MI-pGz. B. Left Ventricular Collagen as a % of the left ventricle in MI-CONT and MI-pGz, with representative microscopic findings. Blue staining denotes fibrosis †p< 0.01 MI-CONT vs. MI-pGz.

Mentions: Infarct size prior to randomization was 38±4%. Treatment with pGz for four weeks decreased transmurality of the infarct from 60± 5% for MI-CONT to 48±4% for MI-pGz (p< 0.01). The ratio of left ventricular wall thickness to the MI thickness was significantly smaller in MI-CONT 0.9±0.5 compared to 3.1 ± 0.7 for MI-pGz (p< 0.01), additionally the amount of left ventricular collagen was 35±4% in MI-CONT compared to 22±4% in pGz treated animals (p< 0.01)(Fig. 3).


Non-invasive technology that improves cardiac function after experimental myocardial infarction: Whole Body Periodic Acceleration (pGz).

Uryash A, Bassuk J, Kurlansky P, Altamirano F, Lopez JR, Adams JA - PLoS ONE (2015)

pGz Reduced Infarct Size, Transmurality and Fibrosis.A. The ratio of left ventricular wall to myocardial infarct length in MI-CONT and MI-pGz, with representative microscopic findings. †p< 0.01 MI-CONT vs. MI-pGz. B. Left Ventricular Collagen as a % of the left ventricle in MI-CONT and MI-pGz, with representative microscopic findings. Blue staining denotes fibrosis †p< 0.01 MI-CONT vs. MI-pGz.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4373845&req=5

pone.0121069.g003: pGz Reduced Infarct Size, Transmurality and Fibrosis.A. The ratio of left ventricular wall to myocardial infarct length in MI-CONT and MI-pGz, with representative microscopic findings. †p< 0.01 MI-CONT vs. MI-pGz. B. Left Ventricular Collagen as a % of the left ventricle in MI-CONT and MI-pGz, with representative microscopic findings. Blue staining denotes fibrosis †p< 0.01 MI-CONT vs. MI-pGz.
Mentions: Infarct size prior to randomization was 38±4%. Treatment with pGz for four weeks decreased transmurality of the infarct from 60± 5% for MI-CONT to 48±4% for MI-pGz (p< 0.01). The ratio of left ventricular wall thickness to the MI thickness was significantly smaller in MI-CONT 0.9±0.5 compared to 3.1 ± 0.7 for MI-pGz (p< 0.01), additionally the amount of left ventricular collagen was 35±4% in MI-CONT compared to 22±4% in pGz treated animals (p< 0.01)(Fig. 3).

Bottom Line: Ejection fraction and fractional shortening and invasive pressure volume relation indices of afterload and contractility were significantly better in MI-pGz.The latter where associated with decreased infarct transmurality and decreased fibrosis along with increased eNOS, p-eNOS.Additionally, MI-pGz had significantly lower levels of iNOS, inflammatory cytokines (IL-6, TNF-α), and higher level of anti-inflammatory cytokine (IL-10). pGz improved survival and contractile performance, associated with improved myocardial remodeling. pGz may serve as a simple, safe, non-invasive therapeutic modality to improve myocardial function after MI.

View Article: PubMed Central - PubMed

Affiliation: Division of Neonatology, Mount Sinai Medical Center, Miami Beach, FL, United States of America.

ABSTRACT
Myocardial infarction (MI) may produce significant inflammatory changes and adverse ventricular remodeling leading to heart failure and premature death. Pharmacologic, stem cell transplantation, and exercise have not halted the inexorable rise in the prevalence and great economic costs of heart failure despite extensive investigations of such treatments. New therapeutic modalities are needed. Whole Body Periodic Acceleration (pGz) is a non-invasive technology that increases pulsatile shear stress to the endothelium thereby producing several beneficial cardiovascular effects as demonstrated in animal models, normal humans and patients with heart disease. pGz upregulates endothelial derived nitric oxide synthase (eNOS) and its phosphorylation (p-eNOS) to improve myocardial function in models of myocardial stunning and preconditioning. Here we test whether pGz applied chronically after focal myocardial infarction in rats improves functional outcomes from MI. Focal MI was produced by left coronary artery ligation. One day after ligation animals were randomized to receive daily treatments of pGz for four weeks (MI-pGz) or serve as controls (MI-CONT), with an additional group as non-infarction controls (Sham). Echocardiograms and invasive pressure volume loop analysis were carried out. Infarct transmurality, myocardial fibrosis, and markers of inflammatory and anti-inflammatory cytokines were determined along with protein analysis of eNOS, p-eNOS and inducible nitric oxide synthase (iNOS).At four weeks, survival was 80% in MI-pGz vs 50% in MI-CONT (p< 0.01). Ejection fraction and fractional shortening and invasive pressure volume relation indices of afterload and contractility were significantly better in MI-pGz. The latter where associated with decreased infarct transmurality and decreased fibrosis along with increased eNOS, p-eNOS. Additionally, MI-pGz had significantly lower levels of iNOS, inflammatory cytokines (IL-6, TNF-α), and higher level of anti-inflammatory cytokine (IL-10). pGz improved survival and contractile performance, associated with improved myocardial remodeling. pGz may serve as a simple, safe, non-invasive therapeutic modality to improve myocardial function after MI.

No MeSH data available.


Related in: MedlinePlus